| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 104 | 2024 | 261 | 19.600 |
Why?
|
| Asthma | 115 | 2024 | 978 | 15.990 |
Why?
|
| Anti-Asthmatic Agents | 25 | 2023 | 75 | 4.430 |
Why?
|
| Comparative Effectiveness Research | 12 | 2018 | 53 | 3.880 |
Why?
|
| Adrenal Cortex Hormones | 29 | 2024 | 266 | 3.640 |
Why?
|
| Oxygen Inhalation Therapy | 13 | 2023 | 60 | 3.480 |
Why?
|
| Patient Readmission | 8 | 2023 | 352 | 2.670 |
Why?
|
| Hospitalization | 28 | 2024 | 877 | 2.520 |
Why?
|
| Humans | 321 | 2024 | 89356 | 2.480 |
Why?
|
| Models, Biological | 15 | 2016 | 1765 | 2.270 |
Why?
|
| Practice Guidelines as Topic | 25 | 2022 | 1047 | 2.130 |
Why?
|
| Signal Transduction | 13 | 2016 | 3384 | 2.070 |
Why?
|
| Forced Expiratory Volume | 30 | 2023 | 125 | 1.940 |
Why?
|
| Evidence-Based Medicine | 11 | 2021 | 433 | 1.860 |
Why?
|
| United States | 72 | 2024 | 6989 | 1.820 |
Why?
|
| Administration, Inhalation | 30 | 2024 | 190 | 1.800 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 435 | 1.760 |
Why?
|
| Muscarinic Antagonists | 5 | 2022 | 58 | 1.750 |
Why?
|
| Bronchodilator Agents | 17 | 2024 | 66 | 1.730 |
Why?
|
| Patient Education as Topic | 8 | 2017 | 360 | 1.720 |
Why?
|
| Patient Discharge | 12 | 2022 | 320 | 1.710 |
Why?
|
| Research Design | 15 | 2022 | 599 | 1.630 |
Why?
|
| Home Care Services | 5 | 2020 | 73 | 1.610 |
Why?
|
| Spirometry | 19 | 2024 | 68 | 1.610 |
Why?
|
| Disease Progression | 29 | 2024 | 1489 | 1.510 |
Why?
|
| Glucocorticoids | 9 | 2022 | 358 | 1.500 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 9 | 2024 | 23 | 1.440 |
Why?
|
| Male | 151 | 2024 | 42411 | 1.410 |
Why?
|
| Pulmonary Medicine | 9 | 2020 | 46 | 1.410 |
Why?
|
| Middle Aged | 118 | 2024 | 25974 | 1.410 |
Why?
|
| Quality of Life | 22 | 2024 | 1668 | 1.400 |
Why?
|
| Smoking | 16 | 2023 | 621 | 1.380 |
Why?
|
| Patient Outcome Assessment | 8 | 2022 | 84 | 1.370 |
Why?
|
| Female | 151 | 2024 | 46202 | 1.360 |
Why?
|
| Chemotaxis | 6 | 2010 | 73 | 1.360 |
Why?
|
| Critical Care | 8 | 2021 | 382 | 1.350 |
Why?
|
| Adult | 104 | 2024 | 26607 | 1.320 |
Why?
|
| Randomized Controlled Trials as Topic | 18 | 2022 | 838 | 1.310 |
Why?
|
| Lung | 21 | 2023 | 1263 | 1.310 |
Why?
|
| Biomedical Research | 3 | 2023 | 398 | 1.250 |
Why?
|
| Vital Capacity | 15 | 2023 | 68 | 1.240 |
Why?
|
| Emergency Service, Hospital | 11 | 2024 | 521 | 1.220 |
Why?
|
| Air Pollution, Indoor | 6 | 2023 | 64 | 1.220 |
Why?
|
| Computer Simulation | 8 | 2016 | 1097 | 1.170 |
Why?
|
| Aged | 84 | 2024 | 19165 | 1.130 |
Why?
|
| Metered Dose Inhalers | 4 | 2019 | 33 | 1.110 |
Why?
|
| Severity of Illness Index | 28 | 2022 | 1840 | 1.090 |
Why?
|
| Enzymes | 3 | 2014 | 47 | 1.080 |
Why?
|
| Observational Studies as Topic | 4 | 2023 | 49 | 1.070 |
Why?
|
| Biomarkers | 21 | 2024 | 1767 | 1.010 |
Why?
|
| Oxygen | 6 | 2024 | 743 | 0.990 |
Why?
|
| Smokers | 7 | 2023 | 46 | 0.990 |
Why?
|
| Clinical Trials as Topic | 7 | 2024 | 1150 | 0.950 |
Why?
|
| Healthcare Disparities | 7 | 2024 | 420 | 0.940 |
Why?
|
| Hypoxia | 6 | 2021 | 653 | 0.890 |
Why?
|
| Child | 37 | 2024 | 7174 | 0.890 |
Why?
|
| Cohort Studies | 28 | 2024 | 2872 | 0.890 |
Why?
|
| Natural Gas | 1 | 2023 | 2 | 0.880 |
Why?
|
| Budesonide | 4 | 2024 | 46 | 0.870 |
Why?
|
| Sleep Wake Disorders | 7 | 2022 | 117 | 0.860 |
Why?
|
| Pulmonary Emphysema | 5 | 2022 | 36 | 0.860 |
Why?
|
| Patient Compliance | 9 | 2023 | 231 | 0.850 |
Why?
|
| Dictyostelium | 3 | 2010 | 43 | 0.850 |
Why?
|
| Nebulizers and Vaporizers | 5 | 2023 | 56 | 0.850 |
Why?
|
| Systems Biology | 4 | 2016 | 44 | 0.840 |
Why?
|
| Lung Diseases | 10 | 2023 | 269 | 0.830 |
Why?
|
| Telemedicine | 3 | 2024 | 188 | 0.830 |
Why?
|
| Emergency Medical Services | 3 | 2009 | 238 | 0.800 |
Why?
|
| Telephone | 1 | 2021 | 35 | 0.790 |
Why?
|
| Societies | 1 | 2021 | 14 | 0.780 |
Why?
|
| Social Isolation | 1 | 2021 | 67 | 0.750 |
Why?
|
| Bronchial Thermoplasty | 1 | 2021 | 6 | 0.750 |
Why?
|
| Thoracic Diseases | 1 | 2021 | 27 | 0.740 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 50 | 0.740 |
Why?
|
| Venous Thrombosis | 7 | 2023 | 253 | 0.740 |
Why?
|
| Respiratory Insufficiency | 3 | 2019 | 162 | 0.730 |
Why?
|
| Immunization | 1 | 2021 | 160 | 0.730 |
Why?
|
| Depression | 10 | 2024 | 505 | 0.730 |
Why?
|
| Models, Molecular | 2 | 2016 | 1303 | 0.730 |
Why?
|
| Prospective Studies | 28 | 2023 | 4289 | 0.720 |
Why?
|
| Self Care | 8 | 2022 | 165 | 0.720 |
Why?
|
| Communicable Diseases | 1 | 2021 | 63 | 0.710 |
Why?
|
| Registries | 4 | 2021 | 784 | 0.700 |
Why?
|
| Surveys and Questionnaires | 20 | 2022 | 2624 | 0.700 |
Why?
|
| Data Collection | 3 | 2019 | 375 | 0.690 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2013 | 51 | 0.690 |
Why?
|
| Vaccines | 1 | 2021 | 83 | 0.680 |
Why?
|
| Respiratory Function Tests | 12 | 2023 | 139 | 0.680 |
Why?
|
| Sputum | 8 | 2024 | 35 | 0.670 |
Why?
|
| Patient-Centered Care | 4 | 2016 | 207 | 0.660 |
Why?
|
| Cross-Sectional Studies | 22 | 2024 | 1714 | 0.660 |
Why?
|
| Clinical Decision-Making | 2 | 2021 | 281 | 0.660 |
Why?
|
| Airway Obstruction | 3 | 2022 | 111 | 0.660 |
Why?
|
| Medicaid | 5 | 2024 | 232 | 0.640 |
Why?
|
| Anti-Bacterial Agents | 5 | 2022 | 788 | 0.640 |
Why?
|
| Health Services Accessibility | 5 | 2023 | 428 | 0.640 |
Why?
|
| Eosinophils | 6 | 2023 | 194 | 0.630 |
Why?
|
| Urban Population | 8 | 2021 | 224 | 0.630 |
Why?
|
| Adolescent | 30 | 2024 | 9263 | 0.620 |
Why?
|
| Inpatients | 3 | 2012 | 310 | 0.620 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 6811 | 0.610 |
Why?
|
| Software | 2 | 2021 | 665 | 0.610 |
Why?
|
| Continuity of Patient Care | 3 | 2009 | 172 | 0.610 |
Why?
|
| Risk Assessment | 11 | 2020 | 2303 | 0.600 |
Why?
|
| Activities of Daily Living | 7 | 2014 | 207 | 0.570 |
Why?
|
| Drug Therapy, Combination | 11 | 2022 | 784 | 0.570 |
Why?
|
| Natural Language Processing | 1 | 2017 | 38 | 0.560 |
Why?
|
| Treatment Outcome | 25 | 2023 | 8241 | 0.560 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2009 | 345 | 0.550 |
Why?
|
| Thromboembolism | 4 | 2006 | 120 | 0.550 |
Why?
|
| Respiratory System Agents | 1 | 2016 | 7 | 0.550 |
Why?
|
| Eosinophilia | 4 | 2023 | 84 | 0.550 |
Why?
|
| Formoterol Fumarate | 7 | 2024 | 8 | 0.540 |
Why?
|
| Fluticasone | 4 | 2021 | 30 | 0.540 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 4 | 2024 | 24 | 0.540 |
Why?
|
| Child, Preschool | 18 | 2024 | 3731 | 0.540 |
Why?
|
| Acute Disease | 9 | 2018 | 841 | 0.540 |
Why?
|
| Societies, Medical | 12 | 2021 | 575 | 0.540 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 601 | 0.520 |
Why?
|
| Health Services Research | 2 | 2021 | 137 | 0.520 |
Why?
|
| Retrospective Studies | 24 | 2024 | 9057 | 0.510 |
Why?
|
| Anticoagulants | 6 | 2023 | 427 | 0.510 |
Why?
|
| Cell Compartmentation | 1 | 2015 | 69 | 0.510 |
Why?
|
| Patient Care Bundles | 1 | 2015 | 21 | 0.500 |
Why?
|
| Sleep Medicine Specialty | 4 | 2018 | 9 | 0.500 |
Why?
|
| Transitional Care | 3 | 2021 | 18 | 0.500 |
Why?
|
| Chicago | 8 | 2022 | 1427 | 0.500 |
Why?
|
| Perception | 3 | 2019 | 179 | 0.480 |
Why?
|
| Cell Membrane | 2 | 2009 | 672 | 0.480 |
Why?
|
| Algorithms | 6 | 2013 | 1877 | 0.480 |
Why?
|
| Biological Clocks | 1 | 2015 | 74 | 0.480 |
Why?
|
| Quality of Health Care | 6 | 2024 | 385 | 0.470 |
Why?
|
| Environmental Exposure | 6 | 2022 | 322 | 0.470 |
Why?
|
| Advisory Committees | 5 | 2021 | 89 | 0.470 |
Why?
|
| Methylprednisolone | 1 | 2014 | 64 | 0.470 |
Why?
|
| Insurance, Health | 3 | 2024 | 162 | 0.470 |
Why?
|
| Patient Participation | 2 | 2016 | 224 | 0.460 |
Why?
|
| Primary Health Care | 4 | 2023 | 351 | 0.460 |
Why?
|
| Hospital Mortality | 5 | 2013 | 387 | 0.460 |
Why?
|
| Minority Groups | 3 | 2021 | 146 | 0.460 |
Why?
|
| Cell Cycle | 1 | 2016 | 509 | 0.450 |
Why?
|
| Exercise Therapy | 1 | 2014 | 81 | 0.450 |
Why?
|
| Phosphotransferases | 1 | 2013 | 65 | 0.450 |
Why?
|
| Smoking Cessation | 3 | 2016 | 253 | 0.450 |
Why?
|
| Energy Intake | 2 | 2004 | 97 | 0.440 |
Why?
|
| Fracture Fixation | 2 | 2003 | 31 | 0.440 |
Why?
|
| International Classification of Diseases | 3 | 2016 | 69 | 0.440 |
Why?
|
| Chronic Disease | 8 | 2022 | 950 | 0.440 |
Why?
|
| Air Pollutants | 3 | 2022 | 92 | 0.430 |
Why?
|
| Radius Fractures | 2 | 2003 | 33 | 0.430 |
Why?
|
| Reproducibility of Results | 7 | 2021 | 2758 | 0.420 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 382 | 0.420 |
Why?
|
| Ophthalmology | 2 | 2023 | 43 | 0.420 |
Why?
|
| Motor Activity | 2 | 2014 | 327 | 0.420 |
Why?
|
| Patient Care Management | 1 | 2012 | 30 | 0.420 |
Why?
|
| Length of Stay | 8 | 2021 | 736 | 0.420 |
Why?
|
| Dyspnea | 6 | 2023 | 76 | 0.410 |
Why?
|
| Research Support as Topic | 2 | 2011 | 85 | 0.400 |
Why?
|
| Comorbidity | 8 | 2022 | 949 | 0.400 |
Why?
|
| Precision Medicine | 3 | 2021 | 410 | 0.400 |
Why?
|
| Chest Wall Oscillation | 1 | 2011 | 5 | 0.400 |
Why?
|
| Disease Management | 8 | 2021 | 329 | 0.390 |
Why?
|
| DNA, Mitochondrial | 2 | 2024 | 187 | 0.390 |
Why?
|
| Diffusion of Innovation | 2 | 2016 | 71 | 0.380 |
Why?
|
| Clinical Coding | 1 | 2011 | 24 | 0.380 |
Why?
|
| Ozone | 2 | 2022 | 8 | 0.380 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2018 | 58 | 0.380 |
Why?
|
| Allosteric Regulation | 1 | 2011 | 67 | 0.380 |
Why?
|
| Medicare | 4 | 2023 | 425 | 0.380 |
Why?
|
| Salmeterol Xinafoate | 2 | 2021 | 16 | 0.370 |
Why?
|
| Housing | 3 | 2022 | 45 | 0.370 |
Why?
|
| Academic Medical Centers | 2 | 2011 | 385 | 0.370 |
Why?
|
| Critical Illness | 3 | 2016 | 306 | 0.370 |
Why?
|
| Health Status Indicators | 4 | 2014 | 103 | 0.370 |
Why?
|
| Caregivers | 5 | 2016 | 160 | 0.370 |
Why?
|
| Logistic Models | 13 | 2023 | 1213 | 0.370 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2010 | 27 | 0.360 |
Why?
|
| Allergens | 3 | 2006 | 183 | 0.360 |
Why?
|
| Respiratory Tract Diseases | 3 | 2013 | 45 | 0.360 |
Why?
|
| Health Care Costs | 2 | 2018 | 235 | 0.360 |
Why?
|
| Knowledge | 1 | 2010 | 29 | 0.360 |
Why?
|
| Equipment Failure | 1 | 2011 | 121 | 0.360 |
Why?
|
| Prevalence | 8 | 2020 | 1243 | 0.350 |
Why?
|
| Shoulder Impingement Syndrome | 2 | 2000 | 2 | 0.350 |
Why?
|
| Tiotropium Bromide | 3 | 2019 | 4 | 0.350 |
Why?
|
| Patient Safety | 2 | 2023 | 218 | 0.340 |
Why?
|
| Air Pollution | 2 | 2022 | 92 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 5 | 2021 | 225 | 0.340 |
Why?
|
| Guideline Adherence | 5 | 2019 | 230 | 0.340 |
Why?
|
| Aspirin | 2 | 2021 | 159 | 0.330 |
Why?
|
| Warfarin | 3 | 2013 | 104 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 387 | 0.330 |
Why?
|
| Teaching | 1 | 2010 | 147 | 0.330 |
Why?
|
| Health Status Disparities | 2 | 2021 | 188 | 0.330 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 54 | 0.330 |
Why?
|
| Emergency Medicine | 1 | 2010 | 125 | 0.320 |
Why?
|
| Risk Factors | 19 | 2022 | 5499 | 0.320 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2010 | 267 | 0.320 |
Why?
|
| Continuous Positive Airway Pressure | 3 | 2017 | 52 | 0.320 |
Why?
|
| Recurrence | 5 | 2011 | 1144 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2012 | 1176 | 0.310 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 319 | 0.310 |
Why?
|
| Social Class | 4 | 2021 | 136 | 0.310 |
Why?
|
| Pregnancy Complications | 3 | 2021 | 345 | 0.300 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2021 | 2661 | 0.300 |
Why?
|
| Control Groups | 1 | 2007 | 15 | 0.300 |
Why?
|
| Medication Adherence | 4 | 2019 | 140 | 0.300 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2007 | 41 | 0.300 |
Why?
|
| Pandemics | 3 | 2022 | 773 | 0.290 |
Why?
|
| Pulmonary Embolism | 4 | 2004 | 228 | 0.290 |
Why?
|
| Longitudinal Studies | 10 | 2023 | 1072 | 0.290 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2004 | 30 | 0.290 |
Why?
|
| Patient Care Planning | 2 | 2005 | 83 | 0.290 |
Why?
|
| Drug Costs | 1 | 2007 | 63 | 0.280 |
Why?
|
| Pest Control | 2 | 2006 | 6 | 0.280 |
Why?
|
| Double-Blind Method | 9 | 2023 | 1719 | 0.280 |
Why?
|
| Interviews as Topic | 4 | 2016 | 339 | 0.280 |
Why?
|
| Social Support | 2 | 2021 | 209 | 0.280 |
Why?
|
| Ambulatory Care | 3 | 2024 | 187 | 0.280 |
Why?
|
| Socioeconomic Factors | 7 | 2021 | 588 | 0.270 |
Why?
|
| Vitamin D Deficiency | 2 | 2020 | 104 | 0.270 |
Why?
|
| Pneumonia, Bacterial | 1 | 2006 | 29 | 0.270 |
Why?
|
| Cell Polarity | 1 | 2006 | 116 | 0.260 |
Why?
|
| Obesity | 5 | 2023 | 971 | 0.260 |
Why?
|
| Feedback, Physiological | 3 | 2011 | 65 | 0.260 |
Why?
|
| Environmental Health | 1 | 2005 | 8 | 0.260 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2006 | 81 | 0.260 |
Why?
|
| Health Status | 4 | 2016 | 371 | 0.260 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2011 | 72 | 0.260 |
Why?
|
| Preventive Medicine | 1 | 2005 | 17 | 0.260 |
Why?
|
| Phosphatidylinositols | 1 | 2005 | 20 | 0.260 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 159 | 0.260 |
Why?
|
| Child Welfare | 1 | 2005 | 38 | 0.250 |
Why?
|
| Follow-Up Studies | 10 | 2023 | 3666 | 0.250 |
Why?
|
| Electronic Health Records | 3 | 2021 | 347 | 0.250 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 289 | 0.250 |
Why?
|
| Mucus | 2 | 2023 | 19 | 0.250 |
Why?
|
| Health Expenditures | 2 | 2016 | 91 | 0.250 |
Why?
|
| Immunoglobulin E | 3 | 2020 | 145 | 0.250 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 461 | 0.240 |
Why?
|
| Infant | 5 | 2023 | 3160 | 0.240 |
Why?
|
| Accountable Care Organizations | 1 | 2024 | 14 | 0.240 |
Why?
|
| Hypersensitivity, Immediate | 2 | 2020 | 63 | 0.240 |
Why?
|
| Multivariate Analysis | 8 | 2017 | 988 | 0.240 |
Why?
|
| Leukocyte Count | 6 | 2019 | 223 | 0.240 |
Why?
|
| Educational Status | 1 | 2005 | 195 | 0.240 |
Why?
|
| Sex Factors | 2 | 2016 | 1066 | 0.240 |
Why?
|
| Isoenzymes | 1 | 2005 | 274 | 0.240 |
Why?
|
| Patient Transfer | 3 | 2016 | 94 | 0.240 |
Why?
|
| Chemotactic Factors | 1 | 2004 | 14 | 0.240 |
Why?
|
| Altitude | 1 | 2024 | 42 | 0.240 |
Why?
|
| Age Factors | 6 | 2022 | 1870 | 0.240 |
Why?
|
| Membrane Lipids | 1 | 2004 | 41 | 0.240 |
Why?
|
| Education | 3 | 2018 | 58 | 0.230 |
Why?
|
| Pragmatic Clinical Trials as Topic | 2 | 2014 | 7 | 0.230 |
Why?
|
| Chemoreceptor Cells | 1 | 2004 | 65 | 0.230 |
Why?
|
| Insurance | 1 | 2024 | 12 | 0.230 |
Why?
|
| Young Adult | 13 | 2022 | 6312 | 0.230 |
Why?
|
| Ventilator Weaning | 1 | 2004 | 24 | 0.230 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2024 | 248 | 0.230 |
Why?
|
| Fractures, Comminuted | 1 | 2003 | 6 | 0.230 |
Why?
|
| Hemorrhage | 2 | 2023 | 280 | 0.230 |
Why?
|
| External Fixators | 1 | 2003 | 19 | 0.230 |
Why?
|
| Hypertension, Pulmonary | 2 | 2005 | 353 | 0.230 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2022 | 192 | 0.220 |
Why?
|
| Biocatalysis | 2 | 2014 | 50 | 0.220 |
Why?
|
| Hand Strength | 2 | 2003 | 52 | 0.220 |
Why?
|
| Thrombophilia | 1 | 2003 | 23 | 0.220 |
Why?
|
| Mucins | 1 | 2023 | 39 | 0.220 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2005 | 290 | 0.220 |
Why?
|
| Neoplasms | 5 | 2022 | 3041 | 0.220 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2018 | 216 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2007 | 1412 | 0.220 |
Why?
|
| Lung Transplantation | 5 | 2010 | 292 | 0.220 |
Why?
|
| Linear Models | 4 | 2017 | 421 | 0.220 |
Why?
|
| Information Systems | 2 | 2021 | 29 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2021 | 143 | 0.220 |
Why?
|
| Intensive Care Units | 2 | 2004 | 396 | 0.210 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 35 | 0.210 |
Why?
|
| Bone Nails | 1 | 2002 | 15 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 47 | 0.210 |
Why?
|
| United Kingdom | 2 | 2019 | 164 | 0.210 |
Why?
|
| Models, Theoretical | 3 | 2015 | 491 | 0.210 |
Why?
|
| Overweight | 1 | 2023 | 119 | 0.210 |
Why?
|
| Eukaryotic Cells | 1 | 2003 | 44 | 0.210 |
Why?
|
| Food Supply | 1 | 2022 | 29 | 0.210 |
Why?
|
| Symptom Assessment | 3 | 2019 | 66 | 0.210 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2002 | 33 | 0.210 |
Why?
|
| Databases, Factual | 4 | 2019 | 856 | 0.210 |
Why?
|
| Cooking | 1 | 2023 | 56 | 0.210 |
Why?
|
| Respiratory Mucosa | 2 | 2021 | 88 | 0.210 |
Why?
|
| Cross Infection | 1 | 2004 | 147 | 0.210 |
Why?
|
| Symptom Flare Up | 2 | 2020 | 12 | 0.210 |
Why?
|
| Time | 2 | 2019 | 76 | 0.210 |
Why?
|
| Hospitals, Teaching | 3 | 2023 | 118 | 0.200 |
Why?
|
| Time Factors | 11 | 2019 | 5338 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 1 | 2004 | 144 | 0.200 |
Why?
|
| Social Segregation | 1 | 2021 | 3 | 0.200 |
Why?
|
| Odds Ratio | 5 | 2016 | 683 | 0.200 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 149 | 0.200 |
Why?
|
| Phosphorylation | 2 | 2015 | 1132 | 0.200 |
Why?
|
| Health Facilities | 1 | 2021 | 36 | 0.200 |
Why?
|
| Factor Xa Inhibitors | 1 | 2021 | 23 | 0.200 |
Why?
|
| Self Report | 2 | 2022 | 297 | 0.200 |
Why?
|
| Space Perception | 1 | 2003 | 117 | 0.190 |
Why?
|
| Secondary Prevention | 2 | 2017 | 158 | 0.190 |
Why?
|
| Government Programs | 2 | 2022 | 8 | 0.190 |
Why?
|
| Information Dissemination | 2 | 2014 | 114 | 0.190 |
Why?
|
| Respiratory Care Units | 3 | 2009 | 4 | 0.190 |
Why?
|
| Hospitals | 2 | 2022 | 299 | 0.190 |
Why?
|
| Bronchoscopy | 2 | 2013 | 161 | 0.190 |
Why?
|
| Pyridones | 1 | 2021 | 56 | 0.190 |
Why?
|
| Causality | 1 | 2021 | 80 | 0.190 |
Why?
|
| Arthroplasty, Replacement, Knee | 2 | 2004 | 114 | 0.190 |
Why?
|
| Muscarinic Agonists | 1 | 2020 | 22 | 0.190 |
Why?
|
| Drug Combinations | 4 | 2023 | 203 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 1 | 2021 | 98 | 0.190 |
Why?
|
| Observer Variation | 3 | 2018 | 610 | 0.190 |
Why?
|
| Lactation | 1 | 2021 | 54 | 0.190 |
Why?
|
| High-Frequency Ventilation | 1 | 2000 | 9 | 0.180 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2021 | 48 | 0.180 |
Why?
|
| Patient Advocacy | 3 | 2018 | 52 | 0.180 |
Why?
|
| Pyrazoles | 1 | 2021 | 150 | 0.180 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 461 | 0.180 |
Why?
|
| Food | 1 | 2021 | 90 | 0.180 |
Why?
|
| Urban Health | 5 | 2011 | 56 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 618 | 0.180 |
Why?
|
| Status Asthmaticus | 1 | 2020 | 9 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 2340 | 0.180 |
Why?
|
| International Cooperation | 1 | 2020 | 125 | 0.180 |
Why?
|
| Macrolides | 2 | 2017 | 31 | 0.180 |
Why?
|
| Massachusetts | 3 | 2024 | 33 | 0.180 |
Why?
|
| Bronchi | 1 | 2021 | 229 | 0.170 |
Why?
|
| Incidence | 4 | 2012 | 1595 | 0.170 |
Why?
|
| Sepsis | 1 | 2004 | 321 | 0.170 |
Why?
|
| Animals | 16 | 2015 | 27369 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2023 | 337 | 0.170 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 26 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2019 | 851 | 0.170 |
Why?
|
| Prescription Drug Overuse | 1 | 2019 | 2 | 0.170 |
Why?
|
| Mometasone Furoate | 1 | 2019 | 18 | 0.170 |
Why?
|
| Muscle, Smooth | 1 | 2021 | 354 | 0.170 |
Why?
|
| Sirolimus | 2 | 2010 | 170 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2021 | 1942 | 0.170 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2019 | 5 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 233 | 0.160 |
Why?
|
| Self Efficacy | 3 | 2019 | 55 | 0.160 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 153 | 0.160 |
Why?
|
| Feasibility Studies | 3 | 2024 | 780 | 0.160 |
Why?
|
| Arthroscopy | 1 | 1999 | 93 | 0.160 |
Why?
|
| Anxiety | 4 | 2022 | 308 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 260 | 0.160 |
Why?
|
| Immunosuppressive Agents | 3 | 2010 | 975 | 0.160 |
Why?
|
| Deprescriptions | 1 | 2018 | 6 | 0.160 |
Why?
|
| Microbiota | 1 | 2024 | 402 | 0.160 |
Why?
|
| Interdisciplinary Studies | 1 | 2018 | 20 | 0.160 |
Why?
|
| Thrombosis | 1 | 2021 | 302 | 0.160 |
Why?
|
| Hand | 1 | 1999 | 133 | 0.160 |
Why?
|
| Amino Acids | 1 | 2019 | 245 | 0.160 |
Why?
|
| Consensus | 1 | 2020 | 356 | 0.160 |
Why?
|
| Health Policy | 2 | 2018 | 185 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2018 | 51 | 0.150 |
Why?
|
| Communication | 1 | 2021 | 460 | 0.150 |
Why?
|
| Calcitonin | 1 | 2017 | 38 | 0.150 |
Why?
|
| Gene Expression | 2 | 2021 | 1310 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1999 | 170 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2016 | 2015 | 0.150 |
Why?
|
| Global Health | 1 | 2019 | 187 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2018 | 111 | 0.150 |
Why?
|
| Osteoarthritis | 1 | 1998 | 74 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 1723 | 0.150 |
Why?
|
| Vitamin D | 1 | 2020 | 269 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.150 |
Why?
|
| History, 21st Century | 1 | 2018 | 181 | 0.140 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 144 | 0.140 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2010 | 136 | 0.140 |
Why?
|
| Patient Selection | 1 | 2021 | 684 | 0.140 |
Why?
|
| Tetracyclines | 1 | 2016 | 4 | 0.140 |
Why?
|
| New England | 1 | 2016 | 10 | 0.140 |
Why?
|
| Southeastern United States | 1 | 2016 | 8 | 0.140 |
Why?
|
| Surgery Department, Hospital | 1 | 1997 | 44 | 0.140 |
Why?
|
| Bacteria | 1 | 2021 | 478 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 312 | 0.140 |
Why?
|
| Self-Management | 1 | 2017 | 42 | 0.140 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 36 | 0.140 |
Why?
|
| Self Administration | 2 | 2009 | 72 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2016 | 24 | 0.140 |
Why?
|
| Synthetic Biology | 1 | 2016 | 15 | 0.140 |
Why?
|
| Inappropriate Prescribing | 1 | 2016 | 19 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2020 | 682 | 0.140 |
Why?
|
| Public Policy | 1 | 2016 | 52 | 0.130 |
Why?
|
| Respiration, Artificial | 4 | 2011 | 352 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 167 | 0.130 |
Why?
|
| Quinolones | 1 | 2016 | 60 | 0.130 |
Why?
|
| Intention | 1 | 2016 | 51 | 0.130 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 73 | 0.130 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 89 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2018 | 463 | 0.130 |
Why?
|
| Biological Products | 1 | 2018 | 155 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 1 | 1996 | 31 | 0.130 |
Why?
|
| Checklist | 1 | 2016 | 61 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2017 | 451 | 0.130 |
Why?
|
| Research Report | 1 | 2015 | 44 | 0.130 |
Why?
|
| Orthopedics | 1 | 1997 | 127 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.130 |
Why?
|
| Clinical Competence | 2 | 2014 | 784 | 0.130 |
Why?
|
| Fatigue | 3 | 2023 | 179 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 645 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2020 | 682 | 0.120 |
Why?
|
| Equipment Design | 1 | 2016 | 417 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2017 | 445 | 0.120 |
Why?
|
| Metabolome | 1 | 2015 | 49 | 0.120 |
Why?
|
| Kinetics | 2 | 2011 | 1528 | 0.120 |
Why?
|
| Fractures, Bone | 2 | 2000 | 128 | 0.120 |
Why?
|
| Cognition Disorders | 2 | 2013 | 235 | 0.120 |
Why?
|
| Recovery of Function | 2 | 2014 | 293 | 0.120 |
Why?
|
| alpha-N-Acetylgalactosaminidase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 8 | 0.120 |
Why?
|
| Fatty Acid Desaturases | 1 | 2014 | 17 | 0.120 |
Why?
|
| Organizational Policy | 2 | 2016 | 55 | 0.120 |
Why?
|
| Cross-Over Studies | 3 | 2020 | 389 | 0.120 |
Why?
|
| Computer Communication Networks | 1 | 2014 | 23 | 0.120 |
Why?
|
| Personnel Selection | 1 | 2015 | 60 | 0.120 |
Why?
|
| Independent Living | 1 | 2014 | 21 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 540 | 0.120 |
Why?
|
| Cholecalciferol | 1 | 2014 | 35 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1996 | 154 | 0.120 |
Why?
|
| Monitoring, Ambulatory | 1 | 2014 | 32 | 0.120 |
Why?
|
| Graft Rejection | 4 | 2010 | 1070 | 0.120 |
Why?
|
| Minority Health | 1 | 2013 | 10 | 0.120 |
Why?
|
| Observation | 2 | 2011 | 38 | 0.110 |
Why?
|
| Pain Measurement | 3 | 2014 | 329 | 0.110 |
Why?
|
| Stroke | 1 | 2023 | 986 | 0.110 |
Why?
|
| Hypertension | 2 | 2012 | 745 | 0.110 |
Why?
|
| Decision Making | 2 | 2011 | 667 | 0.110 |
Why?
|
| Cell Phone | 1 | 2014 | 38 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2015 | 2415 | 0.110 |
Why?
|
| Survival Analysis | 5 | 2011 | 1534 | 0.110 |
Why?
|
| Baltimore | 4 | 2006 | 40 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 83 | 0.110 |
Why?
|
| Patients | 2 | 2016 | 102 | 0.110 |
Why?
|
| Physicians | 2 | 2015 | 690 | 0.110 |
Why?
|
| Gait | 1 | 2014 | 81 | 0.110 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2013 | 9 | 0.110 |
Why?
|
| South Australia | 4 | 2000 | 5 | 0.110 |
Why?
|
| Medical Order Entry Systems | 1 | 2013 | 25 | 0.110 |
Why?
|
| Hospitalists | 1 | 2015 | 135 | 0.110 |
Why?
|
| Program Development | 1 | 2014 | 123 | 0.110 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2017 | 107 | 0.110 |
Why?
|
| Azathioprine | 2 | 2010 | 124 | 0.110 |
Why?
|
| Lymphoma, B-Cell | 1 | 1994 | 106 | 0.110 |
Why?
|
| Inflammation | 1 | 2019 | 972 | 0.110 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2012 | 19 | 0.110 |
Why?
|
| HLA-G Antigens | 1 | 2013 | 52 | 0.110 |
Why?
|
| Glucose | 1 | 2016 | 630 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 533 | 0.110 |
Why?
|
| Faculty, Medical | 1 | 2015 | 186 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2015 | 298 | 0.110 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 711 | 0.100 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 160 | 0.100 |
Why?
|
| Idiopathic Interstitial Pneumonias | 1 | 2012 | 28 | 0.100 |
Why?
|
| Ethanolamines | 2 | 2023 | 24 | 0.100 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2016 | 439 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 142 | 0.100 |
Why?
|
| Protein Interaction Maps | 1 | 2012 | 49 | 0.100 |
Why?
|
| Clinical Protocols | 2 | 2021 | 157 | 0.100 |
Why?
|
| Tacrolimus | 2 | 2010 | 369 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2002 | 2284 | 0.100 |
Why?
|
| T-Lymphocytes | 3 | 1994 | 1224 | 0.100 |
Why?
|
| Tobacco Products | 2 | 2022 | 64 | 0.100 |
Why?
|
| Intermediate Care Facilities | 1 | 2011 | 2 | 0.100 |
Why?
|
| Connective Tissue Diseases | 1 | 2012 | 70 | 0.100 |
Why?
|
| Pneumonia | 1 | 2013 | 182 | 0.100 |
Why?
|
| ROC Curve | 3 | 2017 | 781 | 0.100 |
Why?
|
| Positive-Pressure Respiration | 1 | 2011 | 41 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2012 | 352 | 0.100 |
Why?
|
| Policy Making | 1 | 2011 | 62 | 0.100 |
Why?
|
| Tidal Volume | 2 | 2008 | 54 | 0.100 |
Why?
|
| Medical Records | 1 | 2012 | 120 | 0.100 |
Why?
|
| Residence Characteristics | 3 | 2021 | 202 | 0.100 |
Why?
|
| Mathematical Concepts | 1 | 2011 | 19 | 0.100 |
Why?
|
| Propensity Score | 2 | 2024 | 147 | 0.100 |
Why?
|
| Sleep | 3 | 2020 | 452 | 0.100 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.090 |
Why?
|
| Range of Motion, Articular | 2 | 2003 | 154 | 0.090 |
Why?
|
| Community Health Planning | 1 | 2011 | 21 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2018 | 1223 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2011 | 73 | 0.090 |
Why?
|
| Internal Medicine | 1 | 2015 | 355 | 0.090 |
Why?
|
| Skilled Nursing Facilities | 1 | 2011 | 41 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 155 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1431 | 0.090 |
Why?
|
| Morbidity | 2 | 2022 | 149 | 0.090 |
Why?
|
| Vaccination | 2 | 2023 | 274 | 0.090 |
Why?
|
| Hernia, Hiatal | 1 | 2011 | 38 | 0.090 |
Why?
|
| Neutrophils | 2 | 2017 | 308 | 0.090 |
Why?
|
| Receptors, Cyclic AMP | 1 | 2010 | 2 | 0.090 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2010 | 11 | 0.090 |
Why?
|
| Diglycerides | 1 | 2010 | 22 | 0.090 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2010 | 4 | 0.090 |
Why?
|
| Type C Phospholipases | 1 | 2010 | 28 | 0.090 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2010 | 15 | 0.090 |
Why?
|
| Attitude to Health | 2 | 2004 | 222 | 0.090 |
Why?
|
| Models, Educational | 1 | 2010 | 49 | 0.090 |
Why?
|
| Immunoglobulin G | 2 | 2023 | 465 | 0.090 |
Why?
|
| Peptide Chain Termination, Translational | 1 | 2010 | 6 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2020 | 773 | 0.090 |
Why?
|
| Aminopyridines | 2 | 2023 | 40 | 0.090 |
Why?
|
| Thionucleotides | 1 | 2010 | 56 | 0.090 |
Why?
|
| Biological Variation, Population | 2 | 2020 | 8 | 0.090 |
Why?
|
| Blood Glucose | 2 | 2012 | 836 | 0.090 |
Why?
|
| Radiography | 3 | 2006 | 809 | 0.090 |
Why?
|
| Psychometrics | 3 | 2021 | 330 | 0.090 |
Why?
|
| Pseudopodia | 1 | 2010 | 37 | 0.090 |
Why?
|
| Reimbursement, Incentive | 1 | 2010 | 37 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 179 | 0.090 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2010 | 67 | 0.090 |
Why?
|
| Scopolamine Derivatives | 1 | 2009 | 4 | 0.090 |
Why?
|
| Tibia | 2 | 2004 | 78 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 2401 | 0.090 |
Why?
|
| Leukotriene Antagonists | 1 | 2009 | 25 | 0.080 |
Why?
|
| Albuterol | 2 | 2020 | 35 | 0.080 |
Why?
|
| Heart Failure | 2 | 2016 | 1185 | 0.080 |
Why?
|
| Cockroaches | 2 | 2006 | 10 | 0.080 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 443 | 0.080 |
Why?
|
| Skin Tests | 2 | 2006 | 44 | 0.080 |
Why?
|
| Cyclic AMP | 1 | 2010 | 274 | 0.080 |
Why?
|
| Child Abuse | 1 | 1990 | 84 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 96 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2009 | 39 | 0.080 |
Why?
|
| Physician-Patient Relations | 2 | 2007 | 625 | 0.080 |
Why?
|
| Phenotype | 3 | 2023 | 2440 | 0.080 |
Why?
|
| Hospital Charges | 2 | 2006 | 29 | 0.080 |
Why?
|
| Systems Analysis | 1 | 2009 | 17 | 0.080 |
Why?
|
| Inhalation | 1 | 2008 | 31 | 0.080 |
Why?
|
| Disabled Persons | 2 | 2000 | 73 | 0.080 |
Why?
|
| Veterans | 1 | 2009 | 84 | 0.080 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2011 | 196 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1597 | 0.080 |
Why?
|
| Actin Cytoskeleton | 1 | 2010 | 196 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2010 | 353 | 0.080 |
Why?
|
| Europe | 2 | 2020 | 321 | 0.080 |
Why?
|
| Counseling | 1 | 2010 | 164 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2024 | 54 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2013 | 551 | 0.080 |
Why?
|
| Omalizumab | 1 | 2007 | 8 | 0.080 |
Why?
|
| Managed Care Programs | 3 | 2004 | 42 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2007 | 44 | 0.070 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1988 | 186 | 0.070 |
Why?
|
| Cell Division | 1 | 2009 | 696 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2022 | 1719 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2012 | 171 | 0.070 |
Why?
|
| Parents | 1 | 1990 | 285 | 0.070 |
Why?
|
| Ethics, Research | 1 | 2007 | 52 | 0.070 |
Why?
|
| Congresses as Topic | 2 | 2019 | 113 | 0.070 |
Why?
|
| Motivation | 1 | 2010 | 296 | 0.070 |
Why?
|
| Scleroderma, Limited | 1 | 2006 | 1 | 0.070 |
Why?
|
| Outpatients | 2 | 2022 | 100 | 0.070 |
Why?
|
| Breath Tests | 2 | 2023 | 57 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 3018 | 0.070 |
Why?
|
| Vitamin K | 1 | 2006 | 25 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2009 | 314 | 0.070 |
Why?
|
| Argentina | 1 | 2006 | 13 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 1671 | 0.070 |
Why?
|
| Waist Circumference | 2 | 2018 | 22 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 115 | 0.070 |
Why?
|
| Prognosis | 3 | 2018 | 3783 | 0.070 |
Why?
|
| Genotype | 3 | 2018 | 1849 | 0.070 |
Why?
|
| Splenic Neoplasms | 2 | 1998 | 17 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2019 | 287 | 0.070 |
Why?
|
| Insect Control | 1 | 2005 | 4 | 0.070 |
Why?
|
| Filtration | 1 | 2005 | 25 | 0.070 |
Why?
|
| United States Environmental Protection Agency | 1 | 2005 | 5 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1988 | 211 | 0.070 |
Why?
|
| Bedding and Linens | 1 | 2005 | 13 | 0.070 |
Why?
|
| Survival Rate | 2 | 2009 | 1901 | 0.070 |
Why?
|
| Body Temperature | 1 | 2006 | 125 | 0.070 |
Why?
|
| Axilla | 1 | 2006 | 104 | 0.060 |
Why?
|
| Community-Acquired Infections | 1 | 2006 | 64 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 895 | 0.060 |
Why?
|
| Quantitative Trait Loci | 2 | 2021 | 608 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2012 | 900 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2015 | 1045 | 0.060 |
Why?
|
| Scleroderma, Systemic | 1 | 2005 | 53 | 0.060 |
Why?
|
| Health Education | 1 | 2005 | 105 | 0.060 |
Why?
|
| Bone Cements | 1 | 2004 | 9 | 0.060 |
Why?
|
| Mice | 4 | 2006 | 11761 | 0.060 |
Why?
|
| Knee Prosthesis | 1 | 2004 | 32 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2010 | 945 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2004 | 101 | 0.060 |
Why?
|
| Needs Assessment | 1 | 2005 | 157 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2009 | 341 | 0.060 |
Why?
|
| Enzyme Activation | 1 | 2005 | 698 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2007 | 969 | 0.060 |
Why?
|
| Infant, Newborn | 2 | 2006 | 2485 | 0.060 |
Why?
|
| Specialization | 1 | 2024 | 66 | 0.060 |
Why?
|
| Cardiac Output | 1 | 2004 | 156 | 0.060 |
Why?
|
| Mental Health | 2 | 2016 | 178 | 0.060 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 33 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2024 | 87 | 0.060 |
Why?
|
| APACHE | 1 | 2003 | 22 | 0.060 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2023 | 26 | 0.060 |
Why?
|
| Polysomnography | 2 | 2020 | 151 | 0.060 |
Why?
|
| Immunologic Tests | 1 | 2023 | 6 | 0.060 |
Why?
|
| Educational Measurement | 1 | 2005 | 231 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2005 | 249 | 0.060 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 28 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2005 | 318 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2003 | 80 | 0.050 |
Why?
|
| Parenteral Nutrition | 1 | 2003 | 63 | 0.050 |
Why?
|
| Ventricular Function, Right | 1 | 2004 | 146 | 0.050 |
Why?
|
| Mathematical Computing | 1 | 2003 | 21 | 0.050 |
Why?
|
| Soot | 1 | 2022 | 2 | 0.050 |
Why?
|
| Cotinine | 1 | 2022 | 12 | 0.050 |
Why?
|
| Streptococcus pneumoniae | 1 | 2023 | 49 | 0.050 |
Why?
|
| Transportation | 1 | 2022 | 20 | 0.050 |
Why?
|
| Glycopyrrolate | 1 | 2022 | 4 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 172 | 0.050 |
Why?
|
| Mothers | 1 | 2004 | 142 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2004 | 221 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2023 | 100 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2024 | 268 | 0.050 |
Why?
|
| Gene Expression Regulation | 3 | 2018 | 1976 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2024 | 171 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2023 | 279 | 0.050 |
Why?
|
| Health Services for the Aged | 1 | 2002 | 32 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 90 | 0.050 |
Why?
|
| Hemiterpenes | 1 | 2001 | 6 | 0.050 |
Why?
|
| Weight Loss | 1 | 2023 | 227 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2021 | 16 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 33 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2001 | 70 | 0.050 |
Why?
|
| Muromonab-CD3 | 1 | 2001 | 69 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 1996 | 3011 | 0.050 |
Why?
|
| Asia | 1 | 2001 | 98 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 102 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 871 | 0.050 |
Why?
|
| Biological Transport | 2 | 2013 | 401 | 0.050 |
Why?
|
| Poverty Areas | 3 | 2006 | 37 | 0.050 |
Why?
|
| Bone Density | 1 | 2002 | 209 | 0.050 |
Why?
|
| Ligands | 1 | 2003 | 444 | 0.050 |
Why?
|
| Academies and Institutes | 1 | 2021 | 32 | 0.050 |
Why?
|
| Early Diagnosis | 1 | 2022 | 125 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2003 | 217 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 260 | 0.050 |
Why?
|
| Lymphoma | 1 | 1983 | 265 | 0.050 |
Why?
|
| Prescriptions | 1 | 2021 | 23 | 0.050 |
Why?
|
| Residential Facilities | 1 | 2000 | 3 | 0.050 |
Why?
|
| Pituitary Neoplasms | 1 | 2001 | 69 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 172 | 0.050 |
Why?
|
| Emotions | 1 | 2004 | 349 | 0.050 |
Why?
|
| Expiratory Reserve Volume | 1 | 2000 | 1 | 0.050 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2001 | 160 | 0.050 |
Why?
|
| Students | 1 | 2022 | 170 | 0.050 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2000 | 32 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 152 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 126 | 0.050 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 14 | 0.050 |
Why?
|
| Ankle Injuries | 1 | 2000 | 29 | 0.050 |
Why?
|
| Fibula | 1 | 2000 | 32 | 0.050 |
Why?
|
| Allied Health Personnel | 1 | 2020 | 20 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 146 | 0.050 |
Why?
|
| Hip Fractures | 1 | 2000 | 46 | 0.040 |
Why?
|
| Poverty | 1 | 2022 | 180 | 0.040 |
Why?
|
| Bone Screws | 1 | 2000 | 45 | 0.040 |
Why?
|
| Alcoholic Intoxication | 1 | 2000 | 32 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2001 | 289 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 53 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 227 | 0.040 |
Why?
|
| Residual Volume | 1 | 2019 | 2 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 2001 | 211 | 0.040 |
Why?
|
| Fracture Fixation, Internal | 1 | 2000 | 67 | 0.040 |
Why?
|
| Total Lung Capacity | 1 | 2019 | 5 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2021 | 102 | 0.040 |
Why?
|
| Occupational Therapy | 1 | 1999 | 16 | 0.040 |
Why?
|
| Occupations | 1 | 1999 | 25 | 0.040 |
Why?
|
| Research | 1 | 2021 | 252 | 0.040 |
Why?
|
| Isoleucine | 1 | 2019 | 17 | 0.040 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2019 | 12 | 0.040 |
Why?
|
| Leucine | 1 | 2019 | 60 | 0.040 |
Why?
|
| Valine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Macrophages | 1 | 2022 | 571 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2019 | 20 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 92 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2019 | 53 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2019 | 43 | 0.040 |
Why?
|
| Metabolomics | 1 | 2019 | 75 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2018 | 18 | 0.040 |
Why?
|
| Orthopedic Procedures | 1 | 2000 | 129 | 0.040 |
Why?
|
| Culturally Competent Care | 1 | 2018 | 12 | 0.040 |
Why?
|
| Functional Laterality | 1 | 1999 | 200 | 0.040 |
Why?
|
| Motivational Interviewing | 1 | 2018 | 20 | 0.040 |
Why?
|
| Phylogeny | 1 | 2024 | 1187 | 0.040 |
Why?
|
| Problem Solving | 1 | 2018 | 54 | 0.040 |
Why?
|
| Italy | 1 | 2018 | 108 | 0.040 |
Why?
|
| Self Concept | 1 | 2019 | 133 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 10 | 0.040 |
Why?
|
| Self-Injurious Behavior | 1 | 2000 | 110 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 109 | 0.040 |
Why?
|
| Risk | 2 | 2014 | 657 | 0.040 |
Why?
|
| Growth | 1 | 2018 | 43 | 0.040 |
Why?
|
| Prednisone | 2 | 2010 | 259 | 0.040 |
Why?
|
| Diarrhea | 1 | 2019 | 182 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2019 | 192 | 0.040 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2017 | 3 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 135 | 0.040 |
Why?
|
| Aftercare | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2017 | 25 | 0.040 |
Why?
|
| Nasal Polyps | 1 | 2018 | 61 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 266 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 1983 | 580 | 0.040 |
Why?
|
| Fluoroquinolones | 1 | 2017 | 22 | 0.040 |
Why?
|
| Apoptosis | 2 | 2015 | 1717 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2000 | 396 | 0.040 |
Why?
|
| CpG Islands | 1 | 2018 | 157 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2017 | 86 | 0.040 |
Why?
|
| Arthroplasty | 1 | 1997 | 28 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 1994 | 217 | 0.040 |
Why?
|
| Biopsy | 2 | 2013 | 1184 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 742 | 0.040 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 24 | 0.040 |
Why?
|
| Pain | 1 | 1999 | 400 | 0.040 |
Why?
|
| Interleukin-15 | 1 | 2017 | 73 | 0.030 |
Why?
|
| Bronchiolitis Obliterans | 2 | 2010 | 33 | 0.030 |
Why?
|
| Family | 1 | 2018 | 325 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2002 | 717 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 37 | 0.030 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 48 | 0.030 |
Why?
|
| Respiratory Sounds | 1 | 2016 | 34 | 0.030 |
Why?
|
| Benzamides | 1 | 2017 | 237 | 0.030 |
Why?
|
| Cough | 1 | 2016 | 55 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1862 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2016 | 33 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2001 | 1265 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1998 | 261 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 1994 | 922 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 1994 | 739 | 0.030 |
Why?
|
| Cardiac Rehabilitation | 1 | 2014 | 5 | 0.030 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 1994 | 5 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2014 | 31 | 0.030 |
Why?
|
| Costa Rica | 1 | 2014 | 15 | 0.030 |
Why?
|
| Computer Security | 1 | 2014 | 16 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 17 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2014 | 51 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2015 | 107 | 0.030 |
Why?
|
| Support Vector Machine | 1 | 2014 | 25 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 494 | 0.030 |
Why?
|
| Health Planning Guidelines | 1 | 2014 | 22 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2021 | 1374 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 296 | 0.030 |
Why?
|
| Confidentiality | 1 | 2014 | 77 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 1993 | 17 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1994 | 119 | 0.030 |
Why?
|
| Accelerometry | 1 | 2014 | 39 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2014 | 140 | 0.030 |
Why?
|
| Blood Volume | 1 | 1993 | 49 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 165 | 0.030 |
Why?
|
| Base Sequence | 2 | 1994 | 2327 | 0.030 |
Why?
|
| Models, Animal | 2 | 2005 | 277 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1993 | 150 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 657 | 0.030 |
Why?
|
| Fractures, Stress | 1 | 1992 | 10 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2013 | 60 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1992 | 36 | 0.030 |
Why?
|
| Maternal Exposure | 1 | 2013 | 58 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1994 | 3027 | 0.030 |
Why?
|
| Oximetry | 1 | 2013 | 82 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 1993 | 187 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2011 | 38 | 0.030 |
Why?
|
| Osteoporosis | 1 | 2013 | 122 | 0.030 |
Why?
|
| Age Distribution | 1 | 2012 | 200 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 162 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 630 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2011 | 72 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 111 | 0.020 |
Why?
|
| Injections | 1 | 2011 | 116 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2011 | 92 | 0.020 |
Why?
|
| Dementia | 1 | 2013 | 194 | 0.020 |
Why?
|
| Manometry | 1 | 2011 | 44 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 200 | 0.020 |
Why?
|
| Community Participation | 1 | 2011 | 38 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 505 | 0.020 |
Why?
|
| Social Behavior | 1 | 2014 | 299 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2011 | 56 | 0.020 |
Why?
|
| Community Pharmacy Services | 1 | 2011 | 5 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2011 | 14 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 225 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 301 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 415 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 501 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2012 | 253 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2010 | 44 | 0.020 |
Why?
|
| gamma-Globulins | 1 | 1989 | 16 | 0.020 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 1989 | 5 | 0.020 |
Why?
|
| Survivors | 1 | 2011 | 234 | 0.020 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2009 | 38 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 543 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2011 | 479 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2011 | 122 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 1990 | 166 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 1990 | 117 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 618 | 0.020 |
Why?
|
| Social Environment | 1 | 1990 | 187 | 0.020 |
Why?
|
| Public Health | 1 | 2010 | 138 | 0.020 |
Why?
|
| Ventilators, Mechanical | 1 | 2008 | 37 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 146 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1994 | 2018 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2010 | 183 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 1990 | 476 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1989 | 157 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 269 | 0.020 |
Why?
|
| Splenectomy | 1 | 1988 | 82 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 860 | 0.020 |
Why?
|
| Health Promotion | 1 | 2010 | 165 | 0.020 |
Why?
|
| Directly Observed Therapy | 1 | 2006 | 5 | 0.020 |
Why?
|
| Family Practice | 1 | 2007 | 82 | 0.020 |
Why?
|
| Public Housing | 1 | 2006 | 7 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2010 | 605 | 0.020 |
Why?
|
| MEDLINE | 1 | 2006 | 8 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2007 | 280 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 240 | 0.020 |
Why?
|
| Bone Marrow | 1 | 1988 | 445 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2006 | 109 | 0.020 |
Why?
|
| Androstadienes | 1 | 2006 | 72 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2006 | 234 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2005 | 66 | 0.020 |
Why?
|
| Particle Size | 1 | 2005 | 124 | 0.020 |
Why?
|
| Polymethyl Methacrylate | 1 | 2004 | 13 | 0.020 |
Why?
|
| Absenteeism | 1 | 2004 | 10 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2004 | 37 | 0.010 |
Why?
|
| Maryland | 1 | 2004 | 42 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 319 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2004 | 116 | 0.010 |
Why?
|
| Washington | 1 | 2004 | 49 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2004 | 251 | 0.010 |
Why?
|
| Seasons | 1 | 2005 | 237 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2017 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2005 | 590 | 0.010 |
Why?
|
| Knee Joint | 1 | 2004 | 165 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 2003 | 149 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 1983 | 34 | 0.010 |
Why?
|
| Histiocytes | 1 | 1983 | 22 | 0.010 |
Why?
|
| Lymphadenitis | 1 | 1983 | 7 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 308 | 0.010 |
Why?
|
| Swine | 1 | 2004 | 582 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 996 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1983 | 130 | 0.010 |
Why?
|
| Sex Ratio | 1 | 1983 | 23 | 0.010 |
Why?
|
| Arousal | 1 | 2003 | 170 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 899 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 360 | 0.010 |
Why?
|
| Ethane | 1 | 2001 | 2 | 0.010 |
Why?
|
| Sulfur Oxides | 1 | 2001 | 4 | 0.010 |
Why?
|
| Acetone | 1 | 2001 | 6 | 0.010 |
Why?
|
| Pentanes | 1 | 2001 | 4 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 34 | 0.010 |
Why?
|
| Heparin | 1 | 2003 | 185 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2005 | 731 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2001 | 56 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 2001 | 60 | 0.010 |
Why?
|
| Hydrogen Sulfide | 1 | 2001 | 50 | 0.010 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2000 | 10 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 275 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2001 | 275 | 0.010 |
Why?
|
| Triiodothyronine | 1 | 2001 | 344 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 565 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 887 | 0.010 |
Why?
|
| Adenoma | 1 | 2001 | 246 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 996 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1989 | 2566 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1983 | 548 | 0.010 |
Why?
|
| Mutation | 1 | 2010 | 4143 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1998 | 712 | 0.010 |
Why?
|
| Vasculitis | 1 | 1994 | 40 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1994 | 132 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1994 | 306 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 1994 | 313 | 0.010 |
Why?
|
| Methods | 1 | 1993 | 151 | 0.010 |
Why?
|
| Platelet Count | 1 | 1993 | 93 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 1994 | 173 | 0.010 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 1992 | 10 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1992 | 221 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1994 | 394 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 1989 | 19 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1989 | 240 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1993 | 1799 | 0.010 |
Why?
|